However, the expression of value-added and apoptosis-related signals between the groups was very little, and there was no significant difference
Replacement is a last resort, not a backup plan
Elrick H, Stimmler L, Hlad CJ Jr, Arai Y
That comparison is from the studied FDA-approved products under trial conditions - it's relevant context for understanding why tirzepatide's higher efficacy average might justify its slightly higher price point, but it doesn't predict the gap in any individual patient's results
The efficacy and safety data from the STEP 1 trial used in the cost-effectiveness analyses provide further support to the effectiveness of semaglutide 2.4 mg in reducing body weight, SBP, lipid levels and glycaemic control versus the benefits of D&E
Prefer no needles and can manage daily routines